Copyright: ©Author(s) 2026.
World J Gastroenterol. Jan 21, 2027; 33(3): 124080
Published online Jan 21, 2027. doi: 10.3748/wjg.124080
Published online Jan 21, 2027. doi: 10.3748/wjg.124080
Table 1 Published clinical evidence on liver transplantation for intrahepatic cholangiocarcinoma: Patient selection, treatment strategies, and outcomes
| Ref. | Year | n | Incidental/known | 1-year OS | 3-year OS | 1-year DFS | 3-year DFS | Recurr-ence | Neoadjuvant treatment | Adjuvant treatment | LRT |
| Jeong et al[26] | 2026 | 15 | Incidental | 73.3 | 53.3 | NR | NR | Yes (11) | None | CT after recurrence | NR |
| Giguet et al[27] | 2026 | 6 | Known | 100 | 100 | 100 | 44.41 | Yes (3) | GemCis (4); GemCis + durvalumab (1); LV5FU2 + Cis (1) | None | SIRT/Y-90 (6) |
| Asanuma et al[28] | 2026 | 1 | Incidental | 100 | NR | 100 | NR | None | None | None | None |
| Yaqub et al[29] | 2025 | 5 | Known | NR | NR | NR | NR | Yes (2) | Gem-based CT (5); Erdafitinib (1) | None | SIRT/Y-90 (1) |
| Wei et al[30] | 2025 | 124 | Known | 68.2 | 35.5 | 51.0 | 29.3 | Yes (50) | Neoadjuvant therapy (26; mainly GemCis CT) | NR | NR |
| Semaan et al[31] | 2025 | 26 | Known | 96.0 | 82.7 | 70.8 | 56.3 | Yes (11) | Systemic CT (23/26: Gem 22, platinum 20, 5-FU 11, TKI 3) | None | TARE (5), radiation (8), TACE (1), ablation (1) |
| Ma et al[32] | 2025 | 12 | Incidental | 75.0 | 66.7 | 66.7 | 58.3 | NR | None | 2/12; type NR | Pre-LT treatment 3/12; type NR |
| Liguori et al[33] | 2025 | 1 | Incidental | 100 | NR | 100 | NR | None | None | Cap | None |
| De Abreu Neto et al[34] | 2025 | 2 | Incidental | NR | NR | NR | NR | NR | NR | NR | NR |
| Byrne et al[35] | 2025 | 1 | Known | 100 | NR | 100 | NR | None | GemCis; Gem; maintenance; pemigatinib | Pemigatinib | TARE/Y-90 |
| Baimas-George et al[36] | 2025 | 1 | Known | NR | NR | NR | NR | NR | RT | NR | None |
| Zhu et al[37] | 2024 | 40 | Mixed | NR | NR | NR | NR | NR | NR | NR | NR |
| Teixeira et al[38] | 2024 | 1 | Known | 100 | NR | 100 | NR | None | GemCis; Gem maintenance; FOLFOX; 5-FU/LV | NR | TARE/Y-90 × 3 |
| Rodríguez-Espinosa et al[39] | 2024 | 1 | Incidental | 100 | 0 | NR | 0 | Yes (1) | NR | NR | None |
| Remiszewski et al[40] | 2024 | 2 | Incidental | 100 | NR | 100 | NR | None | None | None | None |
| Maspero et al[22] | 2024 | 4 | Known | 100 | 100 | 100 | 100 | None | GemCis (4); pemigatinib (1) | None | TARE/Y-90 (4) |
| Howell et al[41] | 2024 | 153 | Mixed | NR | NR | NR | NR | NR | CT (84/153; regimen NR) | CT (17/153; regimen NR) | NR |
| Fernandes et al[42] | 2024 | 2 | Known | 100 | NR | 100 | NR | None | GemCis (2); durvalumab (1) | NR | None |
| Bednarsch et al[43] | 2024 | 1 | Known | 100 | NR | 100 | NR | None | GemCis | None | None |
| Andraus et al[16] | 2024 | 1 | Known | 100 | NR | 100 | NR | None | GemCis; maintenance GemCis | NR | GemOX/HAIC |
| Schwenk et al[44] | 2023 | 4 | Incidental | 75 | 75 | 75 | 75 | None | NR | NR | NR |
| Huang et al[45] | 2023 | 113 | Mixed | 82.4 | 60.3 | NR | NR | NR | CT (62; regimen NR); radiation (30; modality NR) | NR | NR |
| Garcia-Moreno et al[46] | 2023 | 2 | Incidental | NR | NR | NR | NR | None | NR | None | NR |
| Endo et al[47] | 2023 | 54 | Mixed | NR | 60.52 | NR | NR | NR | NR | NR | NR |
| Safdar et al[48] | 2022 | 40 | Incidental | 82.1 | 68.73 | NR | NR | NR | NR | Cap (1); Doxorubicin (9)3 | TACE (1) |
| Rauchfuß et al[49] | 2022 | 2 | Known (1) | 100 | 100 | 100 | 100 | None | GemCis (1) | NR | SIRT (1) |
| McMillan et al[23] | 2022 | 18 | Known | 100 | 71 | 70 | 52 | Yes (7) | GemCis (16); GemCap (1); FOLFOX (1); XRT (4) | GemCap (6); Cap (2); Gem (1); olaparib (1); ivosidenib (1); Gem + nab-paclitaxel (1); 5-FU (1) | TARE/Y-90 (3); TACE (1); IRE/RFA(1) |
| Lee et al[50] | 2022 | 62 | Mixed | 88.9 | 72.9 | NR4 | NR | NR | NR | NR | NR |
| Kim et al[51] | 2022 | 66 | Mixed | NS | 36.15 | NR | NR | NR | CT (25; regimen NR) | CT (40; regimen NR) | NR |
| Ito et al[52] | 2022 | 30 | Mixed | 80 | 63 | 73 | 46 | NR | CT or LRT alone (6); CT + LRT (4); exact modality NR | 20; regimen NR | TACE/RFA; exact iCCA-specific n NR |
| Brandão et al[53] | 2022 | 8 | Incidental | 37.5 | 37 | 37.5 | 38.0 | NR | None | NR | TACE (8) |
| Abdelrahim et al[55] | 2022 | 7 | Known | 100 | 68.6 | 85.7 | 71.4 | Yes (2) | GemCis (2), Cap (3), FOLFIRI (2) | NR | None |
| Abdelrahim et al[54] | 2022 | 7 | Known | 100 | 75.0 | 100 | 85.7 | Yes (1) | GemCis (7) | NR | NR |
| Ren et al[56] | 2021 | 28 | Mixed | NR | NR6 | NR | NR6 | Yes (15) | GemCis-based CT; exact n NR | NR | TACE/ablation (21; exact split NR) |
| Hue et al[58] | 2021 | 74 | Mixed | 89.4 | 53.07 | NR | NR | NR | CT (52); RT (39); regimen NR | CT (3); regimen NR | NR |
| Hara et al[59] | 2021 | 19 | Incidental | 79.0 | 63.08 | 79.0 | 45.08 | Yes (10) | None | Gem-based CT/TACE/RFA after recurrence | TACE (1) |
| Gruttadauria et al[60] | 2021 | 4 | Incidental (3) | NR | NR | NR | NR | NR | None | NR | SIRT (1) |
| Gruttadauria et al[61] | 2021 | 6 | Incidental (5) | NR | NR | NR | NR | NR | CT (1; regimen NR) | NR | TARE (1); TACE (2); MWA (1) |
| Ren et al[57] | 2020 | 49 | Mixed | NR | NR | NR | NR | Yes (23) | GemCis-based CT; exact n NR | GemCis; timing NR | TACE (18); ablation (8); TACE + ablation (4) |
| Krasnodębski et al[62] | 2020 | 8 | Incidental | 75.0 | 37.5 | 71.4 | 28.6 | NR | NR | NR | NR |
| Herrero Torres et al[63] | 2020 | 1 | Incidental | 100 | 100 | 100 | 100 | None | None | NR | None |
| Hafeez Bhatti et al[64] | 2020 | 9 | Incidental | NR | NR | NR | 63.0 | NR | None | NR | TACE/RFA; exact iCCA-specific n NR |
| De Martin et al[17] | 2020 | 24 | Incidental | NR | NR | NR | NR | NR | NR | NR | NR |
| Mitra et al[65] | 2018 | 1 | Incidental | NR | NR | NR | NR | None | None | NR | None |
| Lunsford et al[21] | 2018 | 6 | Known | 100 | 83.3 | 50 | 50 | Yes (3) | GemCis (6); Erlotinib-containing therapy (3); Gem (3); GemCap (2); Cap + SBRT (1); 5-FU + Gem (1); FOLFIRI (1) | Gem (4); Cape (1); GemCap (1) | None |
| Lee et al[66] | 2018 | 17 | Incidental | 81.3 | NR9 | NR | NR | Yes (5) | None | NR | TACE (13); RFA (1) |
| Jung et al[67] | 2017 | 8 | Incidental | 62.5 | 62.5 | 62.5 | 62.5 | Yes (5) | None | CT after recurrence (1; regimen NR) | TACE (6) |
| Gupta et al[68] | 2017 | 3 | Incidental | NR | NR | NR | NR | NR | NR | NR | NR |
| Elshamy et al[69] | 2017 | 4 | Incidental | NR | NR | NR | NR | Yes (1) | None | CT after recurrence (1; regimen NR) | TACE (2) |
| Takahashi et al[70] | 2016 | 9 | Incidental | NR | NR | NR | NR | NR | None | None | TACE/RFA; exact pure iCCA n NR |
| Serra et al[71] | 2016 | 1 | Incidental | 100 | NR | 0 | 0 | Yes (1) | None | None | None |
| Sapisochin et al[24] | 2016 | 15 | Mixed | 93.0 | 84.0 | 93.0 | 82.0 | Yes (2) | NR | NR | TACE (3); ablation (2); TACE + ablation (1); other (1) |
| Sapisochin et al[24] | 2016 | 33 | Mixed | 79.0 | 50.0 | 70.0 | 53.0 | Yes (17) | NR | NR | TACE (9); ablation (6); TACE + ablation (2); other (1) |
| Rayar et al[72] | 2016 | 1 | Known | 100 | 100 | 100 | 100 | None | LV5FU2-Cis; EBRT | None | TARE Y-90 |
| Lindnér et al[73] | 2015 | 5 | Mixed | NR | 60.0 | NR | NR | NR | NR | NR | NR |
| Facciuto et al[74] | 2015 | 7 | Mixed | NR | NR | NR | NR | Yes (2) | NR | NR | NR |
| Sperling et al[75] | 2014 | 1 | Incidental | 100 | 100 | 100 | 100 | Yes (1) | None | None | Pre-LT TACE; SIRT after recurrence |
| Sapisochin et al[20] | 2014 | 18 | Incidental | NR | NR | NR | NR | NR | None | NR | NR |
| Sapisochin et al[25] | 2014 | 29 | NR | 79.0 | 61.0 | 89.0 | 71.0 | Yes (7) | None | NR | TACE (8); RFA (3); PEI (2) |
| Patkowski et al[76] | 2014 | 6 | Incidental | NR | 25.0 | NR | 0 | Yes (6) | None | Gem/5-FU + doxorubicin + mitomycin | NR |
| Vallin et al[77] | 2013 | 4 | Incidental | 75.0 | 75.0 | 75.0 | 75.0 | Yes (1) | None | None | NR |
| Fukuda et al[78] | 2013 | 1 | Incidental | 0 | 0 | 0 | 0 | Yes (1) | None | None; GemCis after recurrence | None |
| Vera et al[79] | 2012 | 1 | Incidental | 100 | NR | 0 | 0 | Yes (1) | None | GemOX + RT for pain after recurrence | None |
| Hrehoreţ et al[80] | 2012 | 1 | Incidental | 100 | NR | 100 | NR | None | None | GemOX | None |
| Sapisochin et al[81] | 2011 | 4 | Incidental | NR | NR | NR | NR | NR | None | None | LRT (4; modality for pure iCCA NR) |
| Hu and Yan[82] | 2011 | 20 | Incidental | 84.2 | 32.7 | 55.6 | 28.8 | Yes (12) | Yes; type/count NR | NR | NR |
| Hong et al[83] | 2011 | 25 | Known | NR | NR | NR | NR | NR | CT ± RT (9) | CT ± RT (16) | NR |
| Fu et al[84]10 | 2011 | 11 | Mixed | 50.5 | 50.5 | 51.9 | 51.9 | Yes (5) | 3D-CRT (1) | NR | TACE + PEI (1); TACE (1); RFA (1) |
| Friman et al[85] | 2011 | 33 | Mixed | NR | NR | NR | NR | NR | NR | NR | NR |
| Ali et al[86] | 2011 | 2 | Incidental | NR | NR | NR | NR | Yes (2) | None | None | None |
Table 2 Comparative overview of the two main liver transplantation pathways for intrahepatic cholangiocarcinoma
| Feature | Very early/small iCCA in cirrhosis | Unresectable liver-limited iCCA: Neoadjuvant selection pathway |
| Typical liver background | Cirrhosis/end-stage liver disease | Often non-cirrhotic or compensated chronic liver disease |
| Tumor stage | Very early | Locally advanced but liver-limited |
| Classical size threshold | Single tumor ≤ 2 cm | No universally accepted size threshold |
| Expanded threshold under discussion | Selected cirrhotic patients with solitary tumors ≤ 3 cm under consensus/guidance frameworks | Size less important than biological response |
| Diagnosis | Often incidental or HCC-mimicking; biopsy should be pursued when iCCA is intentionally considered for LT | Biopsy-proven iCCA required |
| Main rationale for LT | Treats both tumor and underlying liver disease when resection is unsafe | Provides a curative-intent option for unresectable liver-limited disease |
| Required biology test | Observation/stability with absence of growth or spread | At least 6 months of radiographic stability or response after neoadjuvant therapy |
| Neoadjuvant/bridging therapy | Bridging may be considered depending on waiting time | Systemic chemotherapy with or without selected LRT |
| Mandatory exclusions | Extrahepatic disease, regional lymph node metastasis, peritoneal disease, macrovascular tumor thrombus/definite vascular invasion | Extrahepatic disease, regional lymph node metastasis, peritoneal disease, macrovascular tumor thrombus/definite vascular invasion, progression on therapy |
| Evidence base | Retrospective explant-based studies; meta-analysis; consensus/guidance extension | Small prospective protocol series, mature single-center cohort, and intention-to-treat downstaging studies |
| Current status | Narrowly selected potential indication | Investigational/protocol-driven indication |
Table 3 Factors supporting or arguing against consideration of liver transplantation in intrahepatic cholangiocarcinoma
| Domain | Factors supporting LT consideration | Factors not supporting LT consideration |
| Disease extent | Liver-limited disease | Extrahepatic metastasis or peritoneal disease |
| Nodal status | Radiologically and/or pathologically negative nodes | Suspicious nodes requiring sampling; confirmed regional lymph node metastasis |
| Tumor burden | Solitary small tumor; limited intrahepatic burden; controlled multifocality within protocol | Diffuse uncontrolled multifocal bilobar disease |
| Cirrhosis setting | Very early iCCA in cirrhosis; unsafe resection due to portal hypertension or poor liver reserve | Adequate liver reserve and safely resectable tumor favor resection rather than LT |
| Response to therapy | Durable stability or response for ≥ 6 months after neoadjuvant therapy | Progression during systemic therapy or LRT |
| Tumor markers | Stable or decreasing CA19-9 and CEA kinetics interpreted in clinical context | Clinically concerning rise in CA19-9 and CEA despite treatment |
| Vascular involvement | Vascular proximity or encasement without tumor thrombus or intimal invasion | Macrovascular tumor thrombus or definite intimal vascular invasion |
| Biology | Long observation without progression | Rapid interval growth or early progression |
| Histology | Well-differentiated or moderately differentiated tumor | Poorly differentiated tumor |
| Surgical staging | Negative peritoneal assessment and nodal sampling when performed | Positive peritoneal assessment, positive peritoneal washing, or positive regional lymph nodes |
| Molecular profile | Potentially targetable alteration; no validated high-risk exclusion signal | Potentially adverse molecular alterations as investigational risk signals, not stand-alone exclusion criteria |
| Patient factors | Good performance status; transplant fitness | Frailty, poor performance status, uncontrolled comorbidity |
- Citation: Akbulut S, Yilmaz S. Liver transplantation for intrahepatic cholangiocarcinoma: From contraindication to biology-driven selection. World J Gastroenterol 2027; 33(3): 124080
- URL: https://www.wjgnet.com/1007-9327/full/v33/i3/124080.htm
- DOI: https://dx.doi.org/10.3748/wjg.124080